Navigation Links
Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
Date:7/23/2008

EAST NORRITON, Pa., July 23 /PRNewswire/ -- Tengion Inc., a clinical stage biotechnology company focused on the development of neo-organs and neo-tissues, today announced that it has appointed Mark Stejbach as Vice President, Marketing and Commercial Planning. Mr. Stejbach brings more than twenty years of marketing, sales, finance, and managed care experience from both Merck & Co., Inc. and Biogen, Inc.

"We are very pleased to welcome Mark to the Tengion executive team as we are advancing our Neo-Bladder clinical trial programs along with commercial planning activities," said Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion. "Mark brings extensive experience and a proven track record in both large pharma and biotech, including the successful launch of AVONEX for multiple sclerosis. His broad expertise in managing commercial activities across all stages of product development, and in specialty markets, will provide key insights to Tengion as we continue to grow and move our clinical pipeline toward commercialization in the US and Europe."

Mr. Stejbach started his pharma career at Merck in 1987 and went on to lead marketing campaigns for VASOTEC and PROSCAR. From 1994 to 1997, Mr. Stejbach worked for Biogen, Inc. developing and executing the launch marketing plan for the company's highly successful first marketed product, AVONEX, for multiple sclerosis. He then rejoined Merck in 1997 and since that time has held numerous senior leadership positions within the company including Senior Director roles in market development, specialty sales, marketing, and investor relations; and Vice President, Sales Services prior to his most recent role of Vice President of Managed Care Marketing in Merck's United States Pharmaceutical division. Mr. Stejbach earned his MBA from The Wharton School, University of Pennsylvania, and a BS in mathematics from Virginia Tech. He was recently named a 2008 Emerging Pharma Leader by Pharmaceutical Executive magazine.

"I am thrilled to join Tengion at what is an extremely exciting time for the company," commented Mr. Stejbach. "As Tengion continues to advance its Neo-Bladder Augment, Conduit and Replacement programs, I look forward to helping the Company achieve its ultimate goal of successfully bringing unique and compelling medical advances to patients in need."

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create a functional neo-organ or neo-tissue that is designed to catalyze the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies.


'/>"/>
SOURCE Tengion Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
2. Tengion Appoints Jeff Randall to Board of Directors
3. Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
4. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
5. Innocoll Appoints Anthony H. Wild Ph.D. to Its Board of Directors
6. AMT Appoints Director Global Marketing and Sales
7. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
8. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
9. PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
10. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
11. Transcept Pharmaceuticals Appoints Key Senior Executives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/24/2016)... -- Regular discussions on a range of subjects including policies, debt ... said Poloz. Speaking at a lecture to the ... pointed to the country,s inflation target, which is set by ... "In certain areas there needs to ... goals, why not sit down and address strategy together?" ...
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
Breaking Biology News(10 mins):